Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-12

AUTHORS

David Cella, Lesley Fallowfield, Peter Barker, Jack Cuzick, Gershon Locker, Anthony Howell, On behalf of the ATAC Trialistsȁ9 Group

ABSTRACT

The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer. Here we report mature HRQoL outcomes from the ATAC trial, comparing anastrozole with tamoxifen as primary adjuvant therapy for postmenopausal women with localized breast cancer. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, and every 6 months thereafter. Baseline characteristics in the HRQoL sub-protocol were well balanced between the anastrozole (n = 335) and tamoxifen (n = 347) groups in the primary analysis population. As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years. There were no statistically significant differences between treatment groups in ES total scores. Consistent with the 2-year analysis, there were differences between treatment groups in patient-reported side effects: diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen. Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen. In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups. More... »

PAGES

273-284

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6

DOI

http://dx.doi.org/10.1007/s10549-006-9260-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007691459

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16944295


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anastrozole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Status", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Odds Ratio", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Dropouts", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Feinberg School of Medicine, Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Suite 100, 60201, Evanston, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cella", 
        "givenName": "David", 
        "id": "sg:person.012000260477.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012000260477.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brighton and Sussex Medical School", 
          "id": "https://www.grid.ac/institutes/grid.414601.6", 
          "name": [
            "Psychosocial Oncology Group, Brighton & Sussex Medical School, Cancer Research UK, Brighton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fallowfield", 
        "givenName": "Lesley", 
        "id": "sg:person.01063165262.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063165262.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Alderley Park, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barker", 
        "givenName": "Peter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research UK", 
          "id": "https://www.grid.ac/institutes/grid.11485.39", 
          "name": [
            "Wolfson Institute of Preventive Medicine, Cancer Research UK, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cuzick", 
        "givenName": "Jack", 
        "id": "sg:person.01136740201.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136740201.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Feinberg School of Medicine, Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Suite 100, 60201, Evanston, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Locker", 
        "givenName": "Gershon", 
        "id": "sg:person.01272673224.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272673224.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Manchester", 
          "id": "https://www.grid.ac/institutes/grid.5379.8", 
          "name": [
            "Department of Medical Oncology, Christie Hospital, Cancer Research UK, University of Manchester, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Howell", 
        "givenName": "Anthony", 
        "id": "sg:person.01005610111.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "On behalf of the ATAC Trialists\u02019 Group", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2005.03.3654", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000710653"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)66544-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001690029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)66544-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001690029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdj044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005294863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa040331", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007910288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.09.121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014233996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0163278705275340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014870899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0163278705275340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014870899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.11.181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018532459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.11.181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018532459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(04)17666-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031625479"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006263818115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032185952", 
          "https://doi.org/10.1023/a:1006263818115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-55647-0_9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034162993", 
          "https://doi.org/10.1007/978-3-642-55647-0_9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-55647-0_9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034162993", 
          "https://doi.org/10.1007/978-3-642-55647-0_9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)09088-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039621510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.08.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041745060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jclinepi.2004.01.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049369635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.2.322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074768316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1993.11.3.570", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082809601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.3.974", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083057211"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-12", 
    "datePublishedReg": "2006-12-01", 
    "description": "The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer. Here we report mature HRQoL outcomes from the ATAC trial, comparing anastrozole with tamoxifen as primary adjuvant therapy for postmenopausal women with localized breast cancer. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, and every 6 months thereafter. Baseline characteristics in the HRQoL sub-protocol were well balanced between the anastrozole (n = 335) and tamoxifen (n = 347) groups in the primary analysis population. As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years. There were no statistically significant differences between treatment groups in ES total scores. Consistent with the 2-year analysis, there were differences between treatment groups in patient-reported side effects: diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen. Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen. In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10549-006-9260-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "100"
      }
    ], 
    "name": "Quality of Life of Postmenopausal Women in the ATAC (\u201cArimidex\u201d, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer", 
    "pagination": "273-284", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "24a2e793006455c2e95d9174a9ffe550bfdffa496963c99468f00070ccc232f0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16944295"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-006-9260-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007691459"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-006-9260-6", 
      "https://app.dimensions.ai/details/publication/pub.1007691459"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13093_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10549-006-9260-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6'


 

This table displays all metadata directly associated to this object as RDF triples.

250 TRIPLES      21 PREDICATES      65 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-006-9260-6 schema:about N0a98b6fe319142f9899b048212dadcdc
2 N0e24529510624b4eab6d4a965daf114d
3 N105c8fab249d4650a96d793d30e7c978
4 N2f565924e1104beea52fa86d2514c60a
5 N38fcc8decfda444f812d853b82bb4d16
6 N46b69438df964a6e972d96b67424350b
7 N4bb8ad3eb0c94d45b2dc7dd8936df0c1
8 N65018c88fe5e447bacd4903b67e09cb5
9 N88bfb76400d94a1fbac7f8e6f2ffb701
10 N987eeb79c3764d45b28e0162dd2aed4f
11 Na4c2ae0397c0467da2576310e78a6f79
12 Na76521f145b847c59e02e257fb00d4a6
13 Nbaea3d5fed684edbb0c51a3f35a7c8ad
14 Nbce45c0960f146aebf441059e2dc84b1
15 Nc7b54c091e444b0589ba6100993d6da8
16 Nc836c44a61324e41a604ead5c2d618f9
17 Ncf81052f8f694b61b8ccf44b5986cf71
18 Nde11219b574246ea823cc42065b1682f
19 Ne3f535f386974d8eb652444d695bbaf2
20 Nfc94b92921ea45b6ba60a88832813ac6
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author N75048a00009947e1949809d5ba96d965
24 schema:citation sg:pub.10.1007/978-3-642-55647-0_9
25 sg:pub.10.1023/a:1006263818115
26 https://doi.org/10.1016/j.jclinepi.2004.01.012
27 https://doi.org/10.1016/s0140-6736(02)09088-8
28 https://doi.org/10.1016/s0140-6736(04)17666-6
29 https://doi.org/10.1016/s0140-6736(05)66544-0
30 https://doi.org/10.1056/nejmoa040331
31 https://doi.org/10.1093/annonc/mdj044
32 https://doi.org/10.1177/0163278705275340
33 https://doi.org/10.1200/jco.1993.11.3.570
34 https://doi.org/10.1200/jco.1997.15.3.974
35 https://doi.org/10.1200/jco.2001.19.2.322
36 https://doi.org/10.1200/jco.2004.08.029
37 https://doi.org/10.1200/jco.2005.03.3654
38 https://doi.org/10.1200/jco.2005.09.121
39 https://doi.org/10.1200/jco.2005.11.181
40 schema:datePublished 2006-12
41 schema:datePublishedReg 2006-12-01
42 schema:description The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer. Here we report mature HRQoL outcomes from the ATAC trial, comparing anastrozole with tamoxifen as primary adjuvant therapy for postmenopausal women with localized breast cancer. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, and every 6 months thereafter. Baseline characteristics in the HRQoL sub-protocol were well balanced between the anastrozole (n = 335) and tamoxifen (n = 347) groups in the primary analysis population. As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years. There were no statistically significant differences between treatment groups in ES total scores. Consistent with the 2-year analysis, there were differences between treatment groups in patient-reported side effects: diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen. Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen. In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree false
46 schema:isPartOf N06b8bbc9fcaa420aa7c26ea194250617
47 N3d8677e644474c87b0fa47c760b699c7
48 sg:journal.1092777
49 schema:name Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer
50 schema:pagination 273-284
51 schema:productId N81bb2c10dd9045c5a4566bfc1840a16b
52 N8d54b23e764244acafeb145c720e1ee3
53 Na7369602db1e4ad596fe78a89236d426
54 Nbefbbbd029f1495a8be29a411f86386b
55 Ndbc977f1d0b04513b891897a68603c81
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007691459
57 https://doi.org/10.1007/s10549-006-9260-6
58 schema:sdDatePublished 2019-04-11T14:30
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N105ec3f53bef4d50b3aa1da9411060a8
61 schema:url http://link.springer.com/10.1007%2Fs10549-006-9260-6
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N06b8bbc9fcaa420aa7c26ea194250617 schema:issueNumber 3
66 rdf:type schema:PublicationIssue
67 N0a98b6fe319142f9899b048212dadcdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Treatment Outcome
69 rdf:type schema:DefinedTerm
70 N0e24529510624b4eab6d4a965daf114d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Anastrozole
72 rdf:type schema:DefinedTerm
73 N105c8fab249d4650a96d793d30e7c978 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Risk Assessment
75 rdf:type schema:DefinedTerm
76 N105ec3f53bef4d50b3aa1da9411060a8 schema:name Springer Nature - SN SciGraph project
77 rdf:type schema:Organization
78 N10e2381691cc4ffdb74d0151e95c77f2 schema:familyName On behalf of the ATAC Trialistsȁ9 Group
79 rdf:type schema:Person
80 N177688ff925a42709b62da46eacea511 rdf:first sg:person.01005610111.35
81 rdf:rest Na71d1641016647328231d39ab145920b
82 N2eff6117afe44bb396d5428da2fe7681 rdf:first sg:person.01272673224.16
83 rdf:rest N177688ff925a42709b62da46eacea511
84 N2f565924e1104beea52fa86d2514c60a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Breast Neoplasms
86 rdf:type schema:DefinedTerm
87 N38fcc8decfda444f812d853b82bb4d16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Chemotherapy, Adjuvant
89 rdf:type schema:DefinedTerm
90 N3d8677e644474c87b0fa47c760b699c7 schema:volumeNumber 100
91 rdf:type schema:PublicationVolume
92 N46b69438df964a6e972d96b67424350b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Female
94 rdf:type schema:DefinedTerm
95 N4afab19c7cd04b658433757d290e2edf rdf:first N9fd2312e049240ceab9d1bb08f950077
96 rdf:rest Nb3ea2e2e72b44a7ab249a65cf34d52c6
97 N4bb8ad3eb0c94d45b2dc7dd8936df0c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Nitriles
99 rdf:type schema:DefinedTerm
100 N65018c88fe5e447bacd4903b67e09cb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Tamoxifen
102 rdf:type schema:DefinedTerm
103 N728258a2c12049ae9a194e5f3a0a0f4c rdf:first sg:person.01063165262.37
104 rdf:rest N4afab19c7cd04b658433757d290e2edf
105 N75048a00009947e1949809d5ba96d965 rdf:first sg:person.012000260477.10
106 rdf:rest N728258a2c12049ae9a194e5f3a0a0f4c
107 N81bb2c10dd9045c5a4566bfc1840a16b schema:name dimensions_id
108 schema:value pub.1007691459
109 rdf:type schema:PropertyValue
110 N88bfb76400d94a1fbac7f8e6f2ffb701 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Patient Dropouts
112 rdf:type schema:DefinedTerm
113 N8d54b23e764244acafeb145c720e1ee3 schema:name nlm_unique_id
114 schema:value 8111104
115 rdf:type schema:PropertyValue
116 N8fd00018cecb4a2ab94eeaa97d62f837 schema:name Feinberg School of Medicine, Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Suite 100, 60201, Evanston, IL, USA
117 rdf:type schema:Organization
118 N987eeb79c3764d45b28e0162dd2aed4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Antineoplastic Combined Chemotherapy Protocols
120 rdf:type schema:DefinedTerm
121 N9fd2312e049240ceab9d1bb08f950077 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
122 schema:familyName Barker
123 schema:givenName Peter
124 rdf:type schema:Person
125 Na4c2ae0397c0467da2576310e78a6f79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Double-Blind Method
127 rdf:type schema:DefinedTerm
128 Na71d1641016647328231d39ab145920b rdf:first N10e2381691cc4ffdb74d0151e95c77f2
129 rdf:rest rdf:nil
130 Na7369602db1e4ad596fe78a89236d426 schema:name readcube_id
131 schema:value 24a2e793006455c2e95d9174a9ffe550bfdffa496963c99468f00070ccc232f0
132 rdf:type schema:PropertyValue
133 Na76521f145b847c59e02e257fb00d4a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Health Status
135 rdf:type schema:DefinedTerm
136 Nb3ea2e2e72b44a7ab249a65cf34d52c6 rdf:first sg:person.01136740201.43
137 rdf:rest N2eff6117afe44bb396d5428da2fe7681
138 Nbaea3d5fed684edbb0c51a3f35a7c8ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Postmenopause
140 rdf:type schema:DefinedTerm
141 Nbce45c0960f146aebf441059e2dc84b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Follow-Up Studies
143 rdf:type schema:DefinedTerm
144 Nbefbbbd029f1495a8be29a411f86386b schema:name pubmed_id
145 schema:value 16944295
146 rdf:type schema:PropertyValue
147 Nc7b54c091e444b0589ba6100993d6da8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Surveys and Questionnaires
149 rdf:type schema:DefinedTerm
150 Nc836c44a61324e41a604ead5c2d618f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Odds Ratio
152 rdf:type schema:DefinedTerm
153 Ncf81052f8f694b61b8ccf44b5986cf71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Triazoles
155 rdf:type schema:DefinedTerm
156 Nd89cff05dded4eceb71c2b679a5a5eed schema:name Feinberg School of Medicine, Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Suite 100, 60201, Evanston, IL, USA
157 rdf:type schema:Organization
158 Ndbc977f1d0b04513b891897a68603c81 schema:name doi
159 schema:value 10.1007/s10549-006-9260-6
160 rdf:type schema:PropertyValue
161 Nde11219b574246ea823cc42065b1682f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Humans
163 rdf:type schema:DefinedTerm
164 Ne3f535f386974d8eb652444d695bbaf2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Quality of Life
166 rdf:type schema:DefinedTerm
167 Nfc94b92921ea45b6ba60a88832813ac6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Time Factors
169 rdf:type schema:DefinedTerm
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
174 schema:name Oncology and Carcinogenesis
175 rdf:type schema:DefinedTerm
176 sg:journal.1092777 schema:issn 0167-6806
177 1573-7217
178 schema:name Breast Cancer Research and Treatment
179 rdf:type schema:Periodical
180 sg:person.01005610111.35 schema:affiliation https://www.grid.ac/institutes/grid.5379.8
181 schema:familyName Howell
182 schema:givenName Anthony
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35
184 rdf:type schema:Person
185 sg:person.01063165262.37 schema:affiliation https://www.grid.ac/institutes/grid.414601.6
186 schema:familyName Fallowfield
187 schema:givenName Lesley
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063165262.37
189 rdf:type schema:Person
190 sg:person.01136740201.43 schema:affiliation https://www.grid.ac/institutes/grid.11485.39
191 schema:familyName Cuzick
192 schema:givenName Jack
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136740201.43
194 rdf:type schema:Person
195 sg:person.012000260477.10 schema:affiliation Nd89cff05dded4eceb71c2b679a5a5eed
196 schema:familyName Cella
197 schema:givenName David
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012000260477.10
199 rdf:type schema:Person
200 sg:person.01272673224.16 schema:affiliation N8fd00018cecb4a2ab94eeaa97d62f837
201 schema:familyName Locker
202 schema:givenName Gershon
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272673224.16
204 rdf:type schema:Person
205 sg:pub.10.1007/978-3-642-55647-0_9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034162993
206 https://doi.org/10.1007/978-3-642-55647-0_9
207 rdf:type schema:CreativeWork
208 sg:pub.10.1023/a:1006263818115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032185952
209 https://doi.org/10.1023/a:1006263818115
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/j.jclinepi.2004.01.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049369635
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/s0140-6736(02)09088-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039621510
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/s0140-6736(04)17666-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031625479
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1016/s0140-6736(05)66544-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001690029
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1056/nejmoa040331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007910288
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1093/annonc/mdj044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005294863
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1177/0163278705275340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014870899
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.1993.11.3.570 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082809601
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1200/jco.1997.15.3.974 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083057211
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.2001.19.2.322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074768316
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.2004.08.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041745060
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.2005.03.3654 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000710653
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1200/jco.2005.09.121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014233996
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1200/jco.2005.11.181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018532459
238 rdf:type schema:CreativeWork
239 https://www.grid.ac/institutes/grid.11485.39 schema:alternateName Cancer Research UK
240 schema:name Wolfson Institute of Preventive Medicine, Cancer Research UK, London, UK
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.414601.6 schema:alternateName Brighton and Sussex Medical School
243 schema:name Psychosocial Oncology Group, Brighton & Sussex Medical School, Cancer Research UK, Brighton, UK
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
246 schema:name AstraZeneca, Alderley Park, Macclesfield, UK
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.5379.8 schema:alternateName University of Manchester
249 schema:name Department of Medical Oncology, Christie Hospital, Cancer Research UK, University of Manchester, Manchester, UK
250 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...